Guideline for Duration and Selection of Adjuvant Endocrine Therapy in Early‑Stage Breast Cancer

1. Decision Making Based on Nodal Status

Node‑positive patients should receive a total of 10 years of endocrine therapy because they have a higher risk of late recurrence and consistently benefit from extended treatment. (NCCN) 1
Node‑negative patients can stop at 5 years unless additional high‑risk features (large tumor size, high grade, unfavorable gene‑expression profile) are present. (NCCN) 1

Continue the same AI for up to 5 additional years (total 10 years). This recommendation is supported by NCCN (2024) and NCCN (2017). (NCCN) [1][2]
MA17.R phase‑III trial demonstrated that extending AI from 5 to 10 years improves 5‑year disease‑free survival from 91 % to 95 % in high‑risk patients. (NCCN) 1
No overall‑survival benefit has been shown; the advantage is limited to disease‑free survival and reduction of contralateral breast cancer. (NCCN) 1

Postmenopausal patients may either switch to an AI for an additional 5 years (total 10 years) or continue tamoxifen for another 5 years. Both options are backed by high‑quality evidence from the ATLAS and aTTom trials (JCO 2014). (American Society of Clinical Oncology) [3][4]
Premenopausal patients who remain premenopausal should continue tamoxifen to reach 10 years total. (NCCN 2017) 2

Extended AI use markedly increases bone‑related toxicities: bone pain (18 % vs 14 %), fractures (14 % vs 9 %), and new‑onset osteoporosis (11 % vs 6 %). (NCCN) 1
Baseline bone‑density assessment is mandatory before extending AI therapy. (NCCN) 1
Consider adding bisphosphonates or denosumab to preserve bone mineral density during extended AI treatment. (NCCN) 1

After 2–3 years of tamoxifen, postmenopausal node‑positive patients may switch to an AI for an additional 5 years (total 7–8 years). This sequential approach has Category 1 evidence. (NCCN) [1][3]
After 4.5–6 years of tamoxifen, postmenopausal patients may switch to an AI for 5 years (total 10 years). This regimen was the specific strategy tested in the MA17.R trial. (NCCN) [1][2]
If AI intolerance occurs at any point, patients can switch to tamoxifen and complete the total duration according to nodal status. (NCCN) [1][2]

No trial has demonstrated an overall‑survival benefit with AI extension beyond 5 years; benefits are confined to disease‑free survival and second‑cancer prevention. (NCCN) 1
Extending AI therapy in node‑negative, low‑risk patients is not recommended because the absolute benefit is minimal. (NCCN) – citation already covered in nodal‑status section.
Failure to monitor bone health when extending AI therapy is a common error; baseline and periodic bone‑density evaluations are required. (NCCN) 1

Women with node-positive breast cancer should be offered extended aromatase inhibitor (AI) therapy for up to a total of 10 years of adjuvant endocrine treatment, as they have a higher risk of late recurrence and show more consistent benefit from extended therapy 5
Node-positive patients have a higher risk of late recurrence and show more consistent benefit from extended therapy 6, 5
Many women with node-negative breast cancer may be offered extended AI therapy for up to 10 years based on considerations of recurrence risk using established prognostic factors 5
However, the benefits are likely narrower for node-negative patients compared to those with node-positive disease 6
Women with low-risk node-negative tumors should not routinely be offered extended therapy 5

The American Society of Clinical Oncology recommends tamoxifen for a duration of 10 years (Evidence Quality: High, Strength of Recommendation: Strong) 6
Tamoxifen for 5 years, then switch to an AI for up to 5 years, for a total duration of up to 10 years (Evidence Quality: High, Strength of Recommendation: Strong) 6
AI therapy alone should not exceed 5 years in the primary adjuvant setting 6
Total endocrine therapy duration should not exceed 10 years 5

Extended adjuvant hormone therapy prevents distant recurrence 5
Extended adjuvant hormone therapy reduces the risk of second primary breast cancers 5
In the MA.17R trial, extended AI therapy reduced the risk for disease recurrence, contralateral breast cancer, or death by 21% 7

To date, none of the studies have shown improvement in overall survival with longer-duration AI therapy, with benefits primarily in disease-free survival and prevention of second breast cancers 5
Extended therapy carries ongoing risks and side effects that must be weighed against potential benefits 5
Decision should involve shared decision-making between the clinical team and patient 5

Extending AI therapy beyond 5 years without considering patient's nodal status and risk factors 6
Offering extended therapy to low-risk node-negative patients who are unlikely to benefit 5
Failing to consider the risk of second breast cancers when making decisions about extended therapy 5
Extending therapy beyond 10 years total duration, which is not supported by current evidence 5